122 related articles for article (PubMed ID: 10583271)
1. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma.
Cull G; Durrant L; Stainer C; Haynes A; Russell N
Br J Haematol; 1999 Dec; 107(3):648-55. PubMed ID: 10583271
[TBL] [Abstract][Full Text] [Related]
2. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.
Titzer S; Christensen O; Manzke O; Tesch H; Wolf J; Emmerich B; Carsten C; Diehl V; Bohlen H
Br J Haematol; 2000 Mar; 108(4):805-16. PubMed ID: 10792287
[TBL] [Abstract][Full Text] [Related]
3. In vitro priming of myeloma antigen-specific allogeneic donor T cells with idiotype pulsed dendritic cells.
Kim SB; Baskar S; Kwak LW
Leuk Lymphoma; 2003 Jul; 44(7):1201-8. PubMed ID: 12916873
[TBL] [Abstract][Full Text] [Related]
4. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.
Reichardt VL; Milazzo C; Brugger W; Einsele H; Kanz L; Brossart P
Haematologica; 2003 Oct; 88(10):1139-49. PubMed ID: 14555310
[TBL] [Abstract][Full Text] [Related]
5. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma.
Lim SH; Bailey-Wood R
Int J Cancer; 1999 Oct; 83(2):215-22. PubMed ID: 10471530
[TBL] [Abstract][Full Text] [Related]
6. Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma.
Osterborg A; Henriksson L; Mellstedt H
Acta Oncol; 2000; 39(7):797-800. PubMed ID: 11145435
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
Curti A; Tosi P; Comoli P; Terragna C; Ferri E; Cellini C; Massaia M; D'Addio A; Giudice V; Di Bello C; Cavo M; Conte R; Gugliotta G; Baccarani M; Lemoli RM
Br J Haematol; 2007 Nov; 139(3):415-24. PubMed ID: 17910631
[TBL] [Abstract][Full Text] [Related]
8. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients.
Hansson L; Abdalla AO; Moshfegh A; Choudhury A; Rabbani H; Nilsson B; Osterborg A; Mellstedt H
Clin Cancer Res; 2007 Mar; 13(5):1503-10. PubMed ID: 17332295
[TBL] [Abstract][Full Text] [Related]
9. [In vitro anti-myeloma effects induced by myeloma idiotype-protein pulsed dendritic cell vaccine].
Zhang M; Yin XR; Luo YY; Lin X; Wang MC; He PC; Li J; Guo GL; Cai RH; Liu YL
Zhonghua Xue Ye Xue Za Zhi; 2005 Oct; 26(10):593-7. PubMed ID: 16532967
[TBL] [Abstract][Full Text] [Related]
10. B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice.
Cohen S; Haimovich J; Hollander N
J Immunother; 2005; 28(5):461-6. PubMed ID: 16113602
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin 2 in a myeloma model.
Stritzke J; Zunkel T; Steinmann J; Schmitz N; Uharek L; Zeis M
Br J Haematol; 2003 Jan; 120(1):27-35. PubMed ID: 12492573
[TBL] [Abstract][Full Text] [Related]
12. Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma.
Guardino AE; Rajapaksa R; Ong KH; Sheehan K; Levy R
Cytotherapy; 2006; 8(3):277-89. PubMed ID: 16793736
[TBL] [Abstract][Full Text] [Related]
13. Optimizing dendritic cell-based immunotherapy in multiple myeloma.
Yi Q; Desikan R; Barlogie B; Munshi N
Br J Haematol; 2002 May; 117(2):297-305. PubMed ID: 11972511
[TBL] [Abstract][Full Text] [Related]
14. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses.
Osterborg A; Yi Q; Henriksson L; Fagerberg J; Bergenbrant S; Jeddi-Tehrani M; Rudén U; Lefvert AK; Holm G; Mellstedt H
Blood; 1998 Apr; 91(7):2459-66. PubMed ID: 9516146
[TBL] [Abstract][Full Text] [Related]
15. Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma--evaluation of T-cell responses by different read-out systems.
Abdalla AO; Hansson L; Eriksson I; Näsman-Glaser B; Rossmann ED; Rabbani H; Mellstedt H; Osterborg A
Haematologica; 2007 Jan; 92(1):110-4. PubMed ID: 17229643
[TBL] [Abstract][Full Text] [Related]
16. Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells.
Dabadghao S; Bergenbrant S; Anton D; He W; Holm G; Yi Q
Br J Haematol; 1998 Mar; 100(4):647-54. PubMed ID: 9531329
[TBL] [Abstract][Full Text] [Related]
17. Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients.
Bergenbrant S; Yi Q; Osterborg A; Björkholm M; Osby E; Mellstedt H; Lefvert AK; Holm G
Br J Haematol; 1996 Mar; 92(4):840-6. PubMed ID: 8616076
[TBL] [Abstract][Full Text] [Related]
18. Active idiotype vaccination in multiple myeloma. GM-CSF may be an important adjuvant cytokine.
Mellstedt H; Osterborg A
Pathol Biol (Paris); 1999 Feb; 47(2):211-5. PubMed ID: 10192891
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy.
Coscia M; Mariani S; Battaglio S; Di Bello C; Fiore F; Foglietta M; Pileri A; Boccadoro M; Massaia M
Leukemia; 2004 Jan; 18(1):139-45. PubMed ID: 14574332
[TBL] [Abstract][Full Text] [Related]
20. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.
Röllig C; Schmidt C; Bornhäuser M; Ehninger G; Schmitz M; Auffermann-Gretzinger S
J Immunother; 2011 Jan; 34(1):100-6. PubMed ID: 21150718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]